Details of Disease

General Information of Disease (ID: DISL5UOX)

• Disease Name: Acquired immune deficiency syndrome
• Synonyms: acquired immunodeficiency syndrome; acquired immune deficiency syndrome; acquired immunodeficiency disease; AIDS; AIDS, acquired immunodeficiency syndrome; acquired immunodeficiency syndrome, AIDS; acquired immune deficiency
• Disease Class: 1C60-1C62: Human immunodeficiency virus disease
• Definition: A syndrome resulting from the acquired deficiency of cellular immunity caused by the human immunodeficiency virus (HIV). It is characterized by the reduction of the Helper T-lymphocytes in the peripheral blood and the lymph nodes. Symptoms include generalized lymphadenopathy, fever, weight loss, and chronic diarrhea. Patients with AIDS are especially susceptible to opportunistic infections (usually pneumocystis carinii pneumonia, cytomegalovirus (CMV) infections, tuberculosis, candida infections, and cryptococcosis), and the development of malignant neoplasms (usually non-Hodgkin lymphoma and Kaposi sarcoma). The human immunodeficiency virus is transmitted through sexual contact, sharing of contaminated needles, or transfusion of contaminated blood.
• Disease Hierarchy:
  DISHMPS5: T-cell immunodeficiency
  DISO97HC: HIV infectious disease
  DISEM33Q: Infectious disease
  DISL5UOX: Acquired immune deficiency syndrome
• ICD Code:
  ICD-11: ICD-11: 1C62.3
  ICD-9: ICD-9: 42
  Expand ICD-11: '1C62.3
  Expand ICD-10: 'B21.0; 'B21.1; 'B21.2; 'B21.3; 'B21.7; 'B22.0; 'B22.2
  Expand ICD-9: 42
• Disease Identifiers:
  MONDO ID: MONDO_0012268
  MESH ID: D000163
  UMLS CUI: C0001175
  MedGen ID: 99
  SNOMED CT ID: 62479008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VRX496	DMIO4V5	Approved	Antisense drug	[1]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
9-AMINOCAMPTOTHECIN	DMQXYRG	Phase 2	Small molecular drug	[2]
CI-1012	DMLRTN1	Phase 2	Small molecular drug	[3]
CYT 99007	DMMWIHC	Phase 2	NA	[4]
SC-49483	DM180VX	Phase 2	Small molecular drug	[5]
WF-10	DM9680E	Phase 2	Small molecular drug	[6]
AVX101	DMSWZEY	Phase 1	NA	[7]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CS-92	DMGWTDW	Discontinued in Phase 2	Small molecular drug	[8]
HGP-30	DMYHHSO	Discontinued in Phase 2	NA	[9]
LG100268	DM41RK2	Discontinued in Phase 1	Small molecular drug	[10]
RG-201	DMW4G68	Discontinued in Phase 1	NA	[11]
A-76202M	DMRHEWX	Terminated	NA	[12]
DDG-39	DMF1ZNU	Terminated	Small molecular drug	[13]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 21 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCL5	TT9DWLC	Limited	Genetic Variation	[14]
CR2	TT0HUN7	Limited	Biomarker	[15]
APOBEC3G	TTP96KH	Strong	Biomarker	[16]
BCL6	TTC9YX5	Strong	Biomarker	[17]
CA14	TTEYTKG	Strong	Genetic Variation	[18]
CCR8	TTE836A	Strong	Biomarker	[19]
CD209	TTBXIM9	Strong	Biomarker	[20]
CD4	TTN2JFW	Strong	Altered Expression	[21]
CLEC9A	TTGUSRB	Strong	Altered Expression	[22]
CXCL12	TT4UGTF	Strong	Genetic Variation	[23]
CXCR4	TTBID49	Strong	Biomarker	[24]
DDR1	TTI1FPZ	Strong	Genetic Variation	[25]
DHFR	TTYZVDJ	Strong	Biomarker	[26]
DHPS	TTBO2A9	Strong	Genetic Variation	[27]
DUSP5	TTZN92A	Strong	Altered Expression	[28]
HLA-B	TTGS10J	Strong	Genetic Variation	[25]
PAK2	TT279WO	Strong	Altered Expression	[29]
PRCP	TTTJZ4M	Strong	Biomarker	[30]
S100B	TTQ0V86	Strong	Biomarker	[31]
SLK	TT8K4DE	Strong	Biomarker	[32]
IL2	TTF89GD	Definitive	Therapeutic	[33]

This Disease Is Related to 33 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FGF5	OTQXGHBY	Limited	Biomarker	[34]
ACTR2	OT3C8U5T	Strong	Biomarker	[35]
ARC	OTN2QQPG	Strong	Genetic Variation	[36]
ATP6V1E1	OT76J5R9	Strong	Biomarker	[37]
C4BPA	OTHNH6Y8	Strong	Biomarker	[38]
C6orf120	OTPBRZZR	Strong	Biomarker	[39]
CARD14	OTADQHOV	Strong	Biomarker	[38]
CCL3L1	OTQXCYB1	Strong	Genetic Variation	[40]
DGKI	OTDZ602D	Strong	Genetic Variation	[41]
DNAJB12	OTL2ZFTX	Strong	Biomarker	[42]
ENTPD4	OTJ2O8BW	Strong	Altered Expression	[42]
ERVW-1	OTWV8DXJ	Strong	Genetic Variation	[43]
GABBR1	OTU5A52J	Strong	Genetic Variation	[25]
GPAT3	OTJUGPK0	Strong	Biomarker	[44]
HCP5	OTV0YRI8	Strong	Genetic Variation	[25]
IFNA1	OTPMKY0L	Strong	Biomarker	[45]
INTS2	OT2N5TCK	Strong	Altered Expression	[46]
ITIH4	OT460OO1	Strong	Biomarker	[47]
JAM3	OTX0F9QL	Strong	Biomarker	[48]
LAS1L	OTG4I2A1	Strong	Biomarker	[49]
NAF1	OTMJKJAK	Strong	Biomarker	[50]
NCR3	OT20M764	Strong	Altered Expression	[51]
OR12D3	OTQ9XNBB	Strong	Genetic Variation	[25]
OR5V1	OTSYXOD6	Strong	Genetic Variation	[25]
PARD3B	OTGZ43YI	Strong	Genetic Variation	[41]
PSMD8	OTY6X27P	Strong	Biomarker	[37]
PSORS1C1	OT9HK436	Strong	Genetic Variation	[25]
RBL2	OTBQSOE6	Strong	Genetic Variation	[52]
RNF39	OTUQA9JT	Strong	Genetic Variation	[25]
TAT	OT2CJ91O	Strong	Biomarker	[53]
TBATA	OTGDMAAL	Strong	Genetic Variation	[54]
TIA1	OTGPN3P8	Strong	Altered Expression	[55]
TNXB	OTVBWAV5	Strong	Genetic Variation	[25]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018409)
• [2] ClinicalTrials.gov (NCT00001427) A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin. U.S. National Institutes of Health.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007001)
• [4] ClinicalTrials.gov (NCT01339000) Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00000791) A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00002244) A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00097838) Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults. U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002465)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002132)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2808).
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005845)
• [12] Synthesis and biological activity of 4',8-dihydroxyisoflavon-7-yl D-hexopyranosides. Carbohydr Res. 2001 Oct 15;335(4):283-9.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001933)
• [14] The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans.Int J Immunogenet. 2008 Apr;35(2):101-5. doi: 10.1111/j.1744-313X.2007.00743.x. Epub 2008 Jan 24.
• [15] Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS.N Engl J Med. 1995 Jan 5;332(1):12-8. doi: 10.1056/NEJM199501053320103.
• [16] Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy.Curr Drug Targets. 2006 Jul;7(7):881-5. doi: 10.2174/138945006777709610.
• [17] Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.Blood. 1997 May 15;89(10):3755-62.
• [18] A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients.Pharmacogenomics J. 2009 Aug;9(4):265-73. doi: 10.1038/tpj.2009.13. Epub 2009 Apr 21.
• [19] Short communication: evidence of HIV type 1 clade C env clones containing low V3 loop charge obtained from an AIDS patient in India that uses CXCR6 and CCR8 for entry in addition to CCR5.AIDS Res Hum Retroviruses. 2011 Feb;27(2):211-9. doi: 10.1089/aid.2009.0180. Epub 2010 Sep 21.
• [20] RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs.AIDS Res Hum Retroviruses. 2007 May;23(5):713-9. doi: 10.1089/aid.2006.0225.
• [21] New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System.Cells. 2019 Oct 13;8(10):1245. doi: 10.3390/cells8101245.
• [22] The levels of DNGR-1 and its ligand-bearing cells were altered after human and simian immunodeficiency virus infection.Immunol Res. 2017 Aug;65(4):869-879. doi: 10.1007/s12026-017-8925-z.
• [23] The effect of combined polymorphisms in chemokines and chemokine receptors on the clinical course of HIV-1 infection in a Brazilian population.Mem Inst Oswaldo Cruz. 2011 Jun;106(4):408-15. doi: 10.1590/s0074-02762011000400005.
• [24] The Challenge of a "Functional Cure" for AIDS by Gene Modified HSCT Therapy.Curr Stem Cell Res Ther. 2015;10(6):492-8. doi: 10.2174/1574888x10666150519094026.
• [25] Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).J Infect Dis. 2009 Feb 1;199(3):419-26. doi: 10.1086/596067.
• [26] Polymorphisms involving the Pneumocystis jirovecii-related genes in AIDS patients in eastern China.Infect Genet Evol. 2019 Nov;75:103955. doi: 10.1016/j.meegid.2019.103955. Epub 2019 Jul 5.
• [27] Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.J Infect Dis. 2000 Aug;182(2):551-7. doi: 10.1086/315719. Epub 2000 Jul 28.
• [28] Selective variations in vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection.Eur J Immunol. 1995 Jun;25(6):1524-8. doi: 10.1002/eji.1830250608.
• [29] CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.Virology. 2007 Feb 5;358(1):119-35. doi: 10.1016/j.virol.2006.07.053. Epub 2006 Sep 18.
• [30] ITSs genotypes and blood dissemination during acute PCP.J Eukaryot Microbiol. 1997 Nov-Dec;44(6):29S. doi: 10.1111/j.1550-7408.1997.tb05753.x.
• [31] Nef-induced CCL2 Expression Contributes to HIV/SIV Brain Invasion and Neuronal Dysfunction.Front Immunol. 2019 Oct 15;10:2447. doi: 10.3389/fimmu.2019.02447. eCollection 2019.
• [32] Deletion and translocation involving chromosome 3 (p14) in two tumorigenic Kaposi's sarcoma cell lines.J Natl Cancer Inst. 1996 Apr 3;88(7):450-5. doi: 10.1093/jnci/88.7.450.
• [33] Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS.Infection. 1998 Nov-Dec;26(6):368-74. doi: 10.1007/BF02770838.
• [34] Fibroblast growth factor gene expression in AIDS-Kaposi's sarcoma detected by in situ hybridization.Am J Pathol. 1991 Jan;138(1):9-15.
• [35] Inhibiting the Arp2/3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses.Mol Biol Cell. 2004 Dec;15(12):5197-207. doi: 10.1091/mbc.e04-04-0279. Epub 2004 Sep 22.
• [36] Differential expression of tumor necrosis factor alpha and interleukin 1 beta compared with interleukin 6 in monocytes from human immunodeficiency virus-positive individuals measured by polymerase chain reaction.J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):109-15.
• [37] An HTLV-III peptide produced by recombinant DNA is immunoreactive with sera from patients with AIDS.Nature. 1985 May 9-15;315(6015):151-4. doi: 10.1038/315151a0.
• [38] The application of L-PRP in AIDS patients with crural chronic ulcers: A pilot study.Adv Med Sci. 2018 Mar;63(1):140-146. doi: 10.1016/j.advms.2017.10.002. Epub 2017 Nov 6.
• [39] Role of C6ORF120, an N-glycosylated protein, is implicated in apoptosis of CD4?T lymphocytes.Chin Med J (Engl). 2011 Nov;124(21):3560-7.
• [40] CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.PLoS One. 2008 Sep 8;3(9):e3165. doi: 10.1371/journal.pone.0003165.
• [41] Genome-wide association study implicates PARD3B-based AIDS restriction.J Infect Dis. 2011 May 15;203(10):1491-502. doi: 10.1093/infdis/jir046.
• [42] Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs.PLoS One. 2015 Sep 14;10(9):e0136989. doi: 10.1371/journal.pone.0136989. eCollection 2015.
• [43] Loci polymorphisms of the APOBEC3G gene in HIV type 1-infected Brazilians.AIDS Res Hum Retroviruses. 2011 Feb;27(2):137-41. doi: 10.1089/aid.2010.0146. Epub 2010 Sep 28.
• [44] Efficacy of a novel reverse transcriptase-polymerase chain reaction (RT-PCR) for detecting Toxoplasma gondii bradyzoite gene expression in human clinical specimens.Mol Cell Probes. 2002 Feb;16(1):31-9. doi: 10.1006/mcpr.2001.0394.
• [45] Effect of zidovudine therapy in patients with HIV infection on endogenous interferon plasma levels and the hepatic cytochrome P450 enzyme system. Chemotherapy. 1998 May-Jun;44(3):174-80. doi: 10.1159/000007112.
• [46] Expression of int-2 oncogene in Kaposi's sarcoma lesions.J Clin Invest. 1993 Mar;91(3):1191-7. doi: 10.1172/JCI116279.
• [47] Transgenic mice expressing HIV-1 envelope protein gp120 in the brain as an animal model in neuroAIDS research.J Neurovirol. 2018 Apr;24(2):156-167. doi: 10.1007/s13365-017-0584-2. Epub 2017 Oct 26.
• [48] Junctional adhesion molecule C (JAM-C) dimerization aids cancer cell migration and metastasis.Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):638-649. doi: 10.1016/j.bbamcr.2018.01.008. Epub 2018 Jan 31.
• [49] Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders.J Med Virol. 1996 Apr;48(4):344-53. doi: 10.1002/(SICI)1096-9071(199604)48:4<344::AID-JMV8>3.0.CO;2-7.
• [50] Multiple splicing variants of Naf1/ABIN-1 transcripts and their alterations in hematopoietic tumors.Int J Mol Med. 2006 Nov;18(5):917-23.
• [51] Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation.Immunol Lett. 2013 Apr;152(1):16-24. doi: 10.1016/j.imlet.2013.03.003. Epub 2013 Mar 26.
• [52] Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.Am J Pathol. 2000 Mar;156(3):751-60. doi: 10.1016/s0002-9440(10)64941-3.
• [53] Sulfated polymannuroguluronate, a novel anti-acquired immune deficiency syndrome drug candidate, decreased vulnerability of PC12 cells to human immunodeficiency virus tat protein through attenuating calcium overload.J Neurosci Res. 2008 Apr;86(5):1169-77. doi: 10.1002/jnr.21566.
• [54] Spatial genetic structure of two HIV-I-resistant polymorphisms (CCR2-64 I and SDF1-3'A) alleles in population of Shandong Province, China.Biomed Environ Sci. 2005 Aug;18(4):241-53.
• [55] Intratumoral activation of CD8-positive cytotoxic lymphocytes in acquired immunodeficiency syndrome lymphomas.Hum Pathol. 1995 Mar;26(3):284-90. doi: 10.1016/0046-8177(95)90059-4.